(Q38226460)

31 August 2017

title

HIV-hepatitis C virus co-infection in the era of direct-acting antivirals (English)

1 reference

31 August 2017

1 reference

Kian Bichoupan

1

1 reference

31 August 2017

Douglas T Dieterich

series ordinal

2

1 reference

31 August 2017

Valérie Martel-Laferrière

series ordinal

3

1 reference

31 August 2017

publication date

1 September 2014

1 reference

31 August 2017

published in

Current HIV/AIDS reports

1 reference

31 August 2017

volume

11

1 reference

31 August 2017

issue

3

1 reference

31 August 2017

page(s)

241-249

1 reference

All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection.

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Treating HCV in HIV 2013: on the cusp of change

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11904-014-0217-9

Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009.

21 January 2018

1 reference

12 December 2020

Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men--New York City, 2005-2010.

1 reference

12 December 2020

Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection

1 reference

12 December 2020

Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker

1 reference

12 December 2020

Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial

1 reference

12 December 2020

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.

1 reference

12 December 2020

Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance

1 reference

12 December 2020

10.1007/S11904-014-0217-9

Identifiers

DOI

1 reference

release_bwqcnypjjndp3ja777iihk5boe

31 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bwqcnypjjndp3ja777iihk5boe

24 November 2022

mapped directly with Wikidata item

1 reference